Scientific publications
This page offers a representative collection of publications related to the scientific background of Herantis’ drug candidates. A comprehensive PubMed listing of publications can be found by clicking the topic title. Please note that in some cases full-text access to the articles may require payment to the publisher.
HER-096
2024
Kulesskaya, Natalia; Holmström, Kira M.; Huttunen, Henri J. Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson’s disease.
2024
Kira M. Holmström, Katarina Jääskeläinen, Natalia Kulesskaya, Jani Koskinen, Päivi Vuorio, Antti Vuolanto, Marica T. Engström, Mika Scheinin, Charlotte Videbaek, Aleksi Tornio & Henri J. Huttunen. A Phase 1a first-in-human clinical trial of HER-096, a subcutaneously administered cdnf-derived peptidomimetic.
2024
Natalia Kulesskaya, Kira M. Holmström and Henri J. Huttunen. Exploring the multiple mechanisms underlying HER-096 neuroprotection and regeneration.
2023
Natalia Kulesskaya, Arnab Bhattacharjee , Kira M. Holmström , Päivi Vuorio , Alexandre Henriques , Noëlle Callizot , Henri J. Huttunen. HER-096 is a CDNF-derived brain-penetrating peptidomimetic that protects dopaminergic neurons in a mouse synucleinopathy model of Parkinson’s disease
2023
Natalia Kulesskaya, Arnab Bhattacharjee, Kira M. Holmström, Rebecka Holmnäs, Jani Koskinen, Satu Leikas, Sigrid Booms, Antti Vuolanto & Henri J. Huttunen. HER-096 Is a Novel Brain-Penetrating Peptidomimetic That Promotes Proteostasis and Reduces Neuroinflammation in an Aged Mouse Model of Synucleinopathy [AD/PD™ 2023 POSTER]
CDNF-family neurotrophic factors
2024
Huttunen et al. Structural basis of CDNF interaction with the UPR regulator GRP78. Nature Communications (2024)15:8175
2023
Huttunen et al. Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial. Mov. Disord. epub May 22, 2023.
2023
De Lorenzo et al. CDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress. Brain 16: awad087, 2023.
2023
Tseng et al. Augmenting hematoma-scavenging capacity of innate immune cells by CDNF reduces brain injury and promotes functional recovery after intracerebral hemorrhage. Cell Death Dis. 14(2): 128, 2023.
2022
Eesmaa et al. CDNF Interacts with ER Chaperones and Requires UPR Sensors to Promote Neuronal Survival. Int. J. Mol. Sci. 23(16): 9489, 2022.
2022
Lindholm and Saarma. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol. Psych.. 27(3): 1310-1321, 2022.
2021
Albert et al. Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo. Mol. Ther. 29(9): 2821-2840, 2021.
2020
Chalazonitis A, Li Z, Pham TD, Chen J, Rao M, Lindholm P, Saarma M, Lindahl M, Gershon MD. Cerebral dopamine neurotrophic factor is essential for enteric neuronal development, maintenance, and regulation of gastrointestinal transit. J Comp. Neurol. 528(14): 2420-2444, 2020.
2020
Lindahl M, Chalazonitis A, Palm E, Pakarinen E, Danilova T, Pham TD, Setlik W, Rao M, Võikar V, Huotari J, Kopra J, Andressoo JO, Piepponen PT, Airavaara M, Panhelainen A, Gershon MD, Saarma M. Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice. Neurobiol. Dis. 134: 104696, 2020.
2019
Huttunen and Saarma. CDNF Protein Therapy in Parkinson's Disease. Cell Transplant. Apr 4:963689719840290, 2019.
2018
Sousa-Victor P, Jasper H, Neves J. Trophic Factors in Inflammation and Regeneration: The Role of MANF and CDNF. Front. Physiol. 9:1629, 2018.
2007
Lindholm, P Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T, Tuominen RK, Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448: 73-77, 2007.